Enlivex Therapeutics Ltd. (NASDAQ:ENLV – Free Report) – Equities research analysts at HC Wainwright cut their Q2 2026 earnings estimates for Enlivex Therapeutics in a note issued to investors on Monday, August 3rd. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.31) per share for the quarter, down from their prior forecast of ($0.30). HC Wainwright has a “Buy” rating and a $300.00 price target on the stock. The consensus estimate for Enlivex Therapeutics’ current full-year earnings is ($1.19) per share. HC Wainwright also issued estimates for Enlivex Therapeutics’ Q3 2026 earnings at ($0.28) EPS, Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($1.15) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.03) EPS and FY2027 earnings at ($0.21) EPS.
ENLV has been the subject of several other reports. Wall Street Zen raised shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 25th. Zacks Research raised Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $247.50.
Enlivex Therapeutics Trading Down 2.8%
Shares of NASDAQ:ENLV opened at $2.11 on Wednesday. Enlivex Therapeutics has a 52 week low of $1.80 and a 52 week high of $31.50. The company’s 50 day moving average is $7.71 and its two-hundred day moving average is $12.22. The company has a market cap of $35.51 million, a PE ratio of -0.26 and a beta of 1.60.
Hedge Funds Weigh In On Enlivex Therapeutics
Hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE raised its holdings in Enlivex Therapeutics by 53.2% during the first quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock worth $121,000 after purchasing an additional 45,303 shares in the last quarter. Jane Street Group LLC lifted its position in shares of Enlivex Therapeutics by 527.4% during the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after buying an additional 67,886 shares during the last quarter. HRT Financial LP boosted its holdings in shares of Enlivex Therapeutics by 719.4% in the 4th quarter. HRT Financial LP now owns 153,990 shares of the company’s stock valued at $108,000 after buying an additional 135,198 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Enlivex Therapeutics by 99.4% in the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock valued at $221,000 after buying an additional 156,336 shares in the last quarter. Finally, Susquehanna International Group LLP acquired a new position in shares of Enlivex Therapeutics in the 3rd quarter valued at $57,000. 1.02% of the stock is currently owned by hedge funds and other institutional investors.
About Enlivex Therapeutics
Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.
The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.
Featured Articles
- Five stocks we like better than Enlivex Therapeutics
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
